Through its Impact Grants, the Cancer Research Institute funds projects that aim to advance defined scientific and technological goals. These awards stem from ongoing collaborations with individual donors and nonprofit organizations, and aim to address major challenges that would otherwise limit progress in cancer immunotherapy research and drug development.
A program designed to challenge the world's leading scientists and out-of-the box thinkers to create a research plan and assemble a research team that will develop a new technology platform with the potential to transform the field of cancer immunotherapy.
The Cancer Research Institute (CRI) and the Focused Ultrasound Foundation (FUSF) established a partnership with the goal of advancing the development of new focused ultrasound (FUS) and cancer immunotherapy treatments. Grant projects address critical unanswered research questions that will help move the field towards new device/drug combination therapies.
In partnership with Sage Bionetworks (Sage) and the Institute for Systems Biology (ISB), the Cancer Research Institute iAtlas is an online database and web resource designed to help basic and clinical researchers navigate immunological data across multiple tumor types.
In December 2012, CRI and Stand Up to Cancer (SU2C), announced their co-funding of the Cancer Immunology Translational Research Dream Team, whose research has focused on optimizing immunological checkpoint blockade combined with adoptive T cell transfer, two highly promising approaches to cancer immunotherapy.
In 2016, the Cancer Research Institute partnered with the Fibrolamellar Cancer Foundation (FCF), a nonprofit organization devoted to funding research in a rare but deadly form of liver cancer called fibrolamellar hepatocellular carcinoma (FHC), to provide $641,500 to four outstanding scientists whose research is focused on developing immunotherapies for patients with FHC.
Since 1981, the Cancer Research Institute and the Concern Foundation for Cancer Research of Beverly Hills in California have provided joint support to the laboratory of Dr. George Klein at the Karolinska Institute in Stockholm, Sweden. Dr. Klein, who died in December 2016, was one of the world’s leading tumor biologists. He and his colleagues pioneered research into the role of the Epstein-Barr virus in causing Burkitt’s lymphoma (a type of cancer) and other diseases. Moreover, Dr. Klein’s laboratory has been a training center for a large number of outstanding scientists from Russia and other former Communist countries where scientific opportunities have been limited.
Gar Reichman Laboratory
Through the Gar Reichman Fund, CRI supports the work of Dr. Malcolm A.S. Moore, who heads the Gar Reichman Laboratory and holds the Enid A. Haupt Chair in Cell Biology at Memorial Sloan Kettering Cancer Center in New York City. Gar Reichman Foundation was established in 1971, in memory of Gar Reichman, to fund research on leukemia and other blood-related diseases. The foundation entrusted its funds to CRI in 1988.